Drug news
NuPathe re-files transdermal Migraine patch at FDA
FDA has accepted for review the resubmitted new drug application for the transdermal sumatriptan migraine patch NP101 fom NuPathe. The FDA has set 17 January as the new Prescription Drug User Fee Act action date.This will be the first transdermal patch for Migraine ever reviewed by the agency.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins